… High dose DTIC with recombinant human interferon alpha 2b (rhIFN2b) for the treatment of
metastatic malignant melanoma (MMM) [abstract). Proc Am Soc Clin Oncol 1990; 9: 281. 10. …

… phase II study in which the difference in response rates was 4% (95% CI- 17-25%) that a
larger phase III study using this regimen was not indicated. Thus, despite a tolerable IL-2/IFN-a …

… Thirty patients with histologically verified metastatic MM were recruited in our prospective
phase II study. Patient’s entry criteria included age 18 and older, measurable disease, World …

… Several phase II studies have shown impressive response … with cisplatin, carmustine,
dacarbazine and tamoxifen in … alone or in combination with interleukin-2 and interferon alpha-2b. J …

… , albeit mainly in nonrandomized phase II trials.The first published … , dacarbazine, and
carmustine with or without tamoxifen in … versus dacarbazine with interferon alpha-2b and …

… study to characterize the efficacy and safety of dacarbazine … days; carmustine 150 mg/m 2
IV day 1 q 42 days; tamoxifen 20 … ; cisplatin 25 mg/m 2 on days 1–3 q 21days; interferon alpha …

… ± histamine, one had Melacine + interferon, and one had prior paclitaxel and dacarbazine. …
This study shows that the administration of cyclosporine (along with interferon-alpha and IL-2 …

… A randomized trial of dacarbazine and tamoxifen vs. dacarbazine alone revealed an overall
… , et al: Intensive therapy with cisplatin, interleukin-2 and interferon-alpha-2a in patients with …

… Dacarbazine 220 mg/m 2 days 1–3; carmustine 150 mg/m 2 day 1 … phase II study of carmustine
alone or in combination with tumour necrosis factor in patients with advanced melanoma. …

… % have been reported in phase II studies and 18.5% to 30% … phase II trial for first-line treatment
of metastatic melanoma … -2, and interferon alpha-2b in advanced melanoma outpatients: …